Full recovery of a stage IV cancer patient facing COVID-19 pandemic

Authors

DOI:

https://doi.org/10.4322/acr.2020.179

Keywords:

COVID-19, SARS-CoV-2, Cancer, Critical care, Treatment Outcome

Abstract

Coronavirus disease 2019 (COVID-19), first recognized in Wuhan, China, was recently declared a global pandemic by the World Health Organization (WHO). Advanced age and comorbid disease, well-known characteristics in the solid tumor population, have been reported as risk factors for severe disease and death. Cancer-related immunosuppression and its treatments also seem to play an active role in the prognosis, response, and clinical outcomes of these patients. The most effective combination therapy for COVID-19 is still under investigation, and the use of corticosteroids is controversial. Although, as a group, metastatic cancer patients are often considered not to be good candidates for ICU treatment, the individual prognosis should always come into consideration, even in a context of high pressure on medical facilities. We report the case of a stage IV prostate cancer patient infected with SARS-CoV-2 who required ICU admission and recovered from COVID-19 infection. Further studies are needed in order to identify accurate clinical prognostic criteria and provide the best treatment for these challenging patients.

Downloads

Download data is not yet available.

References

World Health Organization (WHO). Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance. Vol.1-2. Geneva: WHO; 2020. p. 1-21.

Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-7. http://dx.doi.org/10.1016/S1470-2045(20)30096-6 PMid:32066541.

Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol. 2009;10(6):589-97. http://dx.doi.org/10.1016/S1470-2045(09)70069-5 PMid:19482247.

Li JY, Duan XF, Wang LP, et al. Selective depletion of regulatory t cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res. 2014;2014:286170. http://dx.doi.org/10.1155/2014/286170 PMid:24868562.

Rodriguez-Morales A, Cardona-Ospina J, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623. http://dx.doi.org/10.1016/j.tmaid.2020.101623 PMid:32179124.

Direção-Geral da Saúde (DGS). Doença pelo novo Coronavírus (COVID-19) – Nova definição de caso. Lisboa: DGS; 2020. Orientação 02/2020 atualizada em 09/03/2020.

Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; pii: S0923-7534(20):36383-3. [Epub ahead of print]. http://dx.doi.org/10.1016/j.annonc.2020.03.296

Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. http://dx.doi.org/10.1001/jama.2020.4683 PMid:32203977.

Schellongowski P, Sperr WR, Wohlfarth P, et al. Critically ill patients with cancer: chances and limitations of intensive care medicine — a narrative review. ESMO Open. 2016;1(1):1-6. http://dx.doi.org/10.1136/esmoopen-2015-000018 PMid:27843637.

Martins RM, Teixeira G, Cortesão E, et al. Recomendações para tratamento médico intensivo em doentes oncológicos. Lisboa: Sociedade Portuguesa de Oncologia; 2020.

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. [Epub ahead of print]. http://dx.doi.org/10.1001/jama.2020.6019 PMid:32282022.

Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020. [Epub ahead of print]. http://dx.doi.org/10.1001/jamainternmed.2020.0994 PMid:32167524.

Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Inten J Antimicrob Agents. 2020. [Epub ahead of print]. https://doi.org/10.1016/j.ijantimicag.2020.105949

Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun, 11:222. https://doi.org/10.1038/s41467-019-13940-6

Mendes JJ, Mergulhão P, Froes F, Paiva JA, Gouveia J. Recommendations from the Sociedade Portuguesa de Cuidados Intensivos and Infection & Sepsis Group for intensive care approach to COVID-19. Rev Bras Ter Intensiva. 2020;32(1):2-10. PMid:32401989.

Downloads

Published

2020-09-06

Issue

Section

Article / Clinical Case Report

How to Cite

Parmanande, A. ., Simão, D. ., Sardinha, M. ., Palma dos Reis, A. F. ., Spencer, A. S. ., Vasco Barreira, J. ., & da Luz, R. . (2020). Full recovery of a stage IV cancer patient facing COVID-19 pandemic. Autopsy and Case Reports, 10(3), e2020179. https://doi.org/10.4322/acr.2020.179